TherapeuticsMD (TXMD) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
TherapeuticsMD Announces Second Quarter 2015 Financial Results
August 6, 2015 4:05 PM EDTCompleted Enrollment of 700 Patients in Phase 3 Rejoice Trial; Topline Data Anticipated in Fourth Quarter of 2015 Patient Recruitment for Phase 3 Replenish Trial Advancing; Enrollment Completion Expected during Second Half of 2015 Management to Host Conference call Today at 4:30 p.m. EDT
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its second quarter financial results for the period ended June 30, 2015.
Second Quarter and Recent Developments
... More